Zymeworks Inc. (NYSE:ZYME) Shares Acquired by Barclays PLC

Barclays PLC boosted its stake in shares of Zymeworks Inc. (NYSE:ZYME - Free Report) by 476.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 154,384 shares of the company's stock after buying an additional 127,595 shares during the period. Barclays PLC owned 0.22% of Zymeworks worth $1,937,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC grew its position in shares of Zymeworks by 84.2% in the 3rd quarter. FMR LLC now owns 3,336 shares of the company's stock worth $42,000 after buying an additional 1,525 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in Zymeworks in the third quarter valued at approximately $47,000. Quest Partners LLC grew its holdings in Zymeworks by 8,049.6% in the second quarter. Quest Partners LLC now owns 9,209 shares of the company's stock worth $78,000 after purchasing an additional 9,096 shares during the last quarter. nVerses Capital LLC acquired a new position in shares of Zymeworks during the third quarter worth $79,000. Finally, MQS Management LLC purchased a new stake in shares of Zymeworks during the 2nd quarter valued at $92,000. Institutional investors own 92.89% of the company's stock.

Zymeworks Price Performance

ZYME remained flat at $14.50 during trading on Friday. 461,479 shares of the company's stock were exchanged, compared to its average volume of 609,735. Zymeworks Inc. has a 12 month low of $7.97 and a 12 month high of $17.70. The stock has a 50-day moving average of $14.25 and a two-hundred day moving average of $12.00. The stock has a market capitalization of $998.73 million, a PE ratio of -9.67 and a beta of 1.12.

Zymeworks (NYSE:ZYME - Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.01. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The firm had revenue of $16.00 million during the quarter, compared to analysts' expectations of $17.90 million. During the same quarter last year, the company posted ($0.41) earnings per share. The firm's revenue was down 3.1% compared to the same quarter last year. As a group, analysts predict that Zymeworks Inc. will post -1.43 earnings per share for the current fiscal year.

Insider Activity at Zymeworks

In other news, Director Ecor1 Capital, Llc acquired 11,958 shares of the firm's stock in a transaction on Tuesday, December 24th. The stock was acquired at an average price of $14.12 per share, for a total transaction of $168,846.96. Following the completion of the transaction, the director now owns 14,704,239 shares in the company, valued at approximately $207,623,854.68. The trade was a 0.08 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.92% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

ZYME has been the topic of several research analyst reports. Citigroup boosted their target price on Zymeworks from $16.00 to $18.00 and gave the stock a "buy" rating in a research note on Monday, November 4th. Wells Fargo & Company boosted their price target on Zymeworks from $12.00 to $14.00 and gave the stock an "equal weight" rating in a research note on Thursday, December 19th. Leerink Partnrs raised shares of Zymeworks from a "hold" rating to a "strong-buy" rating in a research report on Thursday, November 7th. Stifel Nicolaus boosted their target price on shares of Zymeworks from $21.00 to $28.00 and gave the stock a "buy" rating in a research report on Monday, October 28th. Finally, HC Wainwright reaffirmed a "neutral" rating and issued a $12.00 price target on shares of Zymeworks in a report on Friday, November 22nd. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Zymeworks has an average rating of "Moderate Buy" and an average target price of $19.17.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.